Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18965753 | 0.87 | TDP1 (0.38) | ALDH1A1TP53SMN1; SMN2NPC1MAPT | |
| SCHEMBL17339845 | 0.80 | ALDH1A1 (0.36) | ALDH1A1TP53SMN1; SMN2NPC1MAPT | |
| SCHEMBL21515189 | 0.75 | SMN1; SMN2 (0.34) | ALDH1A1TP53SMN1; SMN2NPC1MAPT | |
| SCHEMBL18965684 | 0.72 | TDP1 (0.33) | TDP1 | |
| SCHEMBL8310528 | 0.72 | NPC1 (0.32) | ALDH1A1TP53SMN1; SMN2NPC1MAPT | |
| SCHEMBL19303455 | 0.72 | — | — | |
| SCHEMBL19602751 | 0.72 | TDP1 (0.30) | TDP1 | |
| SCHEMBL18854259 | 0.68 | NPC1 (0.31) | ALDH1A1TP53SMN1; SMN2NPC1MAPT | |
| SCHEMBL19491094 | 0.67 | KDR (0.32) | ALDH1A1TP53SMN1; SMN2MAPTRAB9A | |
| SCHEMBL8343981 | 0.67 | IKBKB (0.34) | ALDH1A1TP53SMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11778893-B2 | Indaceno derivatives as organic semiconductors | CLAP CO., LTD. (KR) | 2023-10-03 | — | — | US | disclosed |
| US-20210384434-A1 | INDACENO DERIVATIVES AS ORGANIC SEMICONDUCTORS | CLAP CO., LTD. (KR) | 2021-12-09 | — | — | US | disclosed |
| US-10669371-B2 | Benzothienothiophene isoindigo polymers | BASF SE (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10388881-B2 | Sorting of carbon nanotubes | BASF SE (DE) | 2019-08-20 | — | — | US | disclosed |
| US-10020456-B2 | Ether-based polymers as photo-crosslinkable dielectrics | BASF SE (DE) | 2018-07-10 | — | — | US | disclosed |
| US-20170250358-A1 | ETHER-BASED POLYMERS AS PHOTO-CROSSLINKABLE DIELECTRICS | BASF SE (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170229657-A1 | SORTING OF CARBON NANOTUBES | CLAP CO., LTD. (KR) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210384434-A1 | INDACENO DERIVATIVES AS ORGANIC SEMICONDUCTORS | IPO11, CYP1B1, IDO1 | ALDH1A1 94/4885TP53 1705/4885SMN1; SMN2 3270/4885 |
| US-11778893-B2 | Indaceno derivatives as organic semiconductors | IPO11, CYP1B1, IDO1 | ALDH1A1 94/4885TP53 1705/4885SMN1; SMN2 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.